文献速递冠心病

NSTEMI合并多支血管病变:PCI与CABG的长期结局比较(SWEDEHEART注册研究)

Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry.
PubMed 文献 · Eur Heart J · 2025-01-01

中位随访7.1年,PCI与更高的全因死亡(aOR 1.67)、心肌梗死(aOR 1.51)、再次血运重建(aOR 3.01)和心力衰竭(aOR 1.15)风险相关,CABG在15年内生存获益更优,尤其在高危亚组。

要点

  • NSTEMI多支病变患者中,PCI与更高的死亡、心梗、再次血运重建和心衰风险相关。
  • CABG在15年内提供更长生存获益,尤其<70岁、左主干病变或左室功能不全者。
  • CABG的生存获益随预期寿命缩短而减弱,需个体化选择血运重建策略。

核心结论

  • 在NSTEMI合并多支血管病变患者中,CABG与较低的全因死亡、心肌梗死、再次血运重建和心力衰竭风险相关,尤其在高危亚组。
  • CABG的生存获益在15年内更明显,但随预期寿命缩短而减弱。

研究设计与样本

  • 采用多水平logistic回归(随访时间作为对数转换的offset变量)及工具变量法的双重稳健调整控制已知和未知混杂。

主要发现

  • 中位随访7.1年,PCI与更高的全因死亡风险相关(aOR 1.67;95%CI 1.54-1.81)。
  • PCI与更高的心肌梗死风险相关(aOR 1.51;95%CI 1.41-1.62),但卒中风险无显著差异。
  • PCI的再次血运重建风险约为CABG的三倍(aOR 3.01;95%CI 2.57-3.51),心力衰竭风险高15%(aOR 1.15;95%CI 1.07-1.25)。
  • CABG在15年内提供更长生存获益,尤其<70岁、左主干病变或左室功能不全患者,但较短时间 Horizon 内获益减弱。

临床怎么用

  • 对NSTEMI合并多支血管病变患者,尤其<70岁、左主干病变或左室功能不全者,应优先考虑CABG以改善长期生存。
  • 预期寿命较短的患者,CABG的生存获益减弱,需结合个体情况权衡血运重建策略。
  • PCI与更高的再次血运重建和心衰风险相关,选择PCI时应加强随访和二级预防。

局限性

  • 观察性注册研究,尽管采用双重稳健调整和工具变量法,仍可能存在残余混杂。
  • 原文未报告具体混杂变量列表、工具变量细节及亚组分析完整数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The long-term outcomes of percutaneous coronary intervention (PCI) vs. coronary artery bypass grafting (CABG) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain debated. METHODS: The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies registry was used to analyse 57 097 revascularized patients with NSTEMI with multivessel disease in Sweden from January 2005 to June 2022. The primary endpoint was all-cause mortality, encompassing both in-hospital and long-term mortality; the secondary endpoints included myocardial infarction (MI), stroke, new revascularization, and heart failure. Multilevel logistic regression with follow-up time as a log-transformed offset variable and double-robust adjustment with the instrumental variable method were applied to control for known and unknown confounders. RESULTS: Percutaneous coronary intervention was the primary therapy in 42 190 (73.9%) patients, while 14 907 (26.1%) received CABG. Percutaneous coronary intervention patients were generally older with more prior cardiovascular events, whereas CABG patients had higher incidences of diabetes, hypertension, left main and three-vessel disease, and reduced ejection fraction. Over a median follow-up of 7.1 years, PCI was associated with higher risks of death [adjusted odds ratio (aOR) 1.67; 95% confidence interval (CI) 1.54-1.81] and MI (aOR 1.51; 95% CI 1.41-1.62) but there was no significant difference in stroke. Repeat revascularization was three times more likely to PCI (aOR 3.01; 95% CI 2.57-3.51), while heart failure risk was 15% higher (aOR 1.15; 95% CI 1.07-1.25). Coronary artery bypass grafting provided longer survival within 15 years, especially in patients under 70 years of age, with left main disease or left ventricular dysfunction, though this benefit diminished over shorter time horizons. CONCLUSIONS: Coronary artery bypass grafting is associated with lower risks of mortality, MI, repeat revascularization, and heart failure in patients with NSTEMI, particularly in high-risk subgroups. However, its survival benefit lessens with shorter life expectancy.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Omerovic E, Råmunddal T, Petursson P, et al. Percutaneous vs. surgical revascularization of non-ST-segment elevation myocardial infarction with multivessel disease: the SWEDEHEART registry. Eur Heart J. 2025. PMID: 39601339. doi:10.1093/eurheartj/ehae700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。